Glioblastoma-Derived Mechanisms of Systemic Immunosuppression

Neurosurgery Clinics of North America

Volumn 21, Issue 1, 2010, Pages 31-42

  Waziri, Allen ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Glioma; Immunity; Immunoregulation; Immunosuppression; Monocyte; T cell

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR;

CELL HETEROGENEITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ANIMALS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; ONCOGENES; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

EID: 70450213189     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2009.08.005     Document Type: Review

References (82)

1. Brooks W.H., Netsky M.G., Normansell D.E., et al. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med 136 6 (1972) 1631-1647
2. Brooks W.H., Caldwell H.D., and Mortara R.H. Immune responses in patients with gliomas. Surg Neurol 2 6 (1974) 419-423
3. Dix A.R., Brooks W.H., Roszman T.L., et al. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100 1-2 (1999) 216-232
4. Wheeler C.J., Black K.L., Liu G., et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68 14 (2008) 5955-5964
5. McComb R.D., and Bigner D.D. The biology of malignant gliomas-a comprehensive survey. Clin Neuropathol 3 3 (1984) 93-106
6. Li A., Walling J., Kotliarov Y., et al. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 6 1 (2008) 21-30
7. Anderson R.C., Elder J.B., Brown M.D., et al. Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro. Clin Immunol 102 1 (2002) 84-95
8. Ogden A.T., Waziri A.E., Lochhead R.A., et al. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 62 2 (2008) 505-514 [discussion: 514-5]
9. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 432 7015 (2004) 396-401
10. Barth R.F. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 36 1 (1998) 91-102
11. Parsa A.T., Chakrabarti I., Hurley P.T., et al. Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy. Neurosurgery 47 4 (2000) 993-999 [discussion: 999-1000]
12. Goldbrunner R.H., Wagner S., Roosen K., et al. Models for assessment of angiogenesis in gliomas. J Neurooncol 50 1-2 (2000) 53-62
13. Assanah M., Lochhead R., Ogden A., et al. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci 26 25 (2006) 6781-6790
14. Shih A.H., Dai C., Hu X., et al. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 64 14 (2004) 4783-4789
15. Waziri A., Killory B., Ogden III A.T., et al. Preferential in situ CD4+CD56+ T cell activation and expansion within human glioblastoma. J Immunol 180 11 (2008) 7673-7680
16. Kennedy B.C., Maier L.M., D'Amico R., et al. Dynamics of central and peripheral immunomodulation in a murine glioma model. BMC Immunol 10 (2009) 11
17. Candolfi M., Curtin J.F., Nichols W.S., et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 85 2 (2007) 133-148
18. Dunn G.P., Dunn I.F., and Curry W.T. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 7 (2007) 12
19. Yu J.S., Lee P.K., Ehtesham M., et al. Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium. J Neurooncol 64 1-2 (2003) 55-61
20. Perrin G., Schnuriger V., Quiquerez A.L., et al. Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset. Int Immunol 11 8 (1999) 1337-1350
21. Ebato M., Nitta T., Yagita H., et al. Skewed distribution of TCR V alpha 7-bearing T cells within tumor-infiltrating lymphocytes of HLA-A24(9)-positive patients with malignant glioma. Immunol Lett 39 1 (1993) 53-64
22. Kempuraj D., Devi R.S., Madhappan B., et al. T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors. Int J Immunopathol Pharmacol 17 1 (2004) 57-64
23. Morford L.A., Elliott L.H., Carlson S.L., et al. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159 9 (1997) 4415-4425
24. Strasser A., Jost P.J., and Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 30 2 (2009) 180-192
25. Didenko V.V., Ngo H.N., Minchew C., et al. Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J Neurosurg 96 3 (2002) 580-584
26. Ichinose M., Masuoka J., Shiraishi T., et al. Fas ligand expression and depletion of T-cell infiltration in astrocytic tumors. Brain Tumor Pathol 18 1 (2001) 37-42
27. Husain N., Chiocca E.A., Rainov N., et al. Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol 95 3 (1998) 287-290
28. Saas P., Walker P.R., Hahne M., et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?. J Clin Invest 99 6 (1997) 1173-1178
29. Frankel B., Longo S.L., and Canute G.W. Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion. J Neurooncol 48 1 (2000) 21-26
30. O'Callaghan C.A., and Bell J.I. Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol Rev 163 (1998) 129-138
31. Wiendl H., Mitsdoerffer M., Hofmeister V., et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 168 9 (2002) 4772-4780
32. Rebmann V., Regel J., Stolke D., et al. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 13 5 (2003) 371-377
33. Wischhusen J., Friese M.A., Mittelbronn M., et al. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol 64 6 (2005) 523-528
34. Mittelbronn M., Simon P., Loffler C., et al. Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. J Neuroimmunol 189 1-2 (2007) 50-58
35. Greenwald R.J., Freeman G.J., and Sharpe A.H. The B7 family revisited. Annu Rev Immunol 23 (2005) 515-548
36. Wintterle S., Schreiner B., Mitsdoerffer M., et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 63 21 (2003) 7462-7467
37. Wilmotte R., Burkhardt K., Kindler V., et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport 16 10 (2005) 1081-1085
38. Parsa A.T., Waldron J.S., Panner A., et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13 1 (2007) 84-88
39. Fontana A., Hengartner H., de Tribolet N., et al. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 132 4 (1984) 1837-1844
40. Schwyzer M., and Fontana A. Partial purification and biochemical characterization of a T cell suppressor factor produced by human glioblastoma cells. J Immunol 134 2 (1985) 1003-1009
41. Wrann M., Bodmer S., de Martin R., et al. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J 6 6 (1987) 1633-1636
42. Roszman T.L., Brooks W.H., and Elliott L.H. Inhibition of lymphocyte responsiveness by a glial tumor cell-derived suppressive factor. J Neurosurg 67 6 (1987) 874-879
43. Kuppner M.C., Hamou M.F., Bodmer S., et al. The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int J Cancer 42 4 (1988) 562-567
44. Bodmer S., Strommer K., Frei K., et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143 10 (1989) 3222-3229
45. Yamada N., Kato M., Yamashita H., et al. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 62 4 (1995) 386-392
46. Constam D.B., Philipp J., Malipiero U.V., et al. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148 5 (1992) 1404-1410
47. Horst H.A., Scheithauer B.W., Kelly P.J., et al. Distribution of transforming growth factor-beta 1 in human astrocytomas. Hum Pathol 23 11 (1992) 1284-1288
48. Krzyszkowski T., Dziedzic T., Czepko R., et al. Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma. Neurol Res 30 3 (2008) 294-296
49. Woiciechowsky C., Asadullah K., Nestler D., et al. Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: effect of tumor extirpation. J Neuroimmunol 84 2 (1998) 164-171
50. Nathoo N., Barnett G.H., and Golubic M. The eicosanoid cascade: possible role in gliomas and meningiomas. J Clin Pathol 57 1 (2004) 6-13
51. Lauro G.M., Di Lorenzo N., Grossi M., et al. Prostaglandin E2 as an immunomodulating factor released in vitro by human glioma cells. Acta Neuropathol 69 3-4 (1986) 278-282
52. Couldwell W.T., Dore-Duffy P., Apuzzo M.L., et al. Malignant glioma modulation of immune function: relative contribution of different soluble factors. J Neuroimmunol 33 2 (1991) 89-96
53. Akasaki Y., Liu G., Chung N.H., et al. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 173 7 (2004) 4352-4359
54. Nitta T., Hishii M., Sato K., et al. Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 649 1-2 (1994) 122-128
55. Huettner C., Paulus W., and Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 146 2 (1995) 317-322
56. Huettner C., Czub S., Kerkau S., et al. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 17 5A (1997) 3217-3224
57. Wagner S., Czub S., Greif M., et al. Microglial/macrophage expression of interleukin 10 in human glioblastomas. Int J Cancer 82 1 (1999) 12-16
58. Samaras V., Piperi C., Korkolopoulou P., et al. Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Mol Cell Biochem 304 1-2 (2007) 343-351
59. Braun D.P., Penn R.D., Flannery A.M., et al. Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas. Neurosurgery 10 2 (1982) 203-209
60. Wood G.W., and Morantz R.A. Depressed T lymphocyte function in brain tumor patients: monocytes as suppressor cells. J Neurooncol 1 2 (1983) 87-94
61. Zou J.P., Morford L.A., Chougnet C., et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 162 8 (1999) 4882-4892
62. Kostianovsky A.M., Maier L.M., Anderson R.C., et al. Astrocytic regulation of human monocytic/microglial activation. J Immunol 181 8 (2008) 5425-5432
63. Ostrand-Rosenberg S., and Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182 8 (2009) 4499-4506
64. Ogden A.T., Horgan D., Waziri A., et al. Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosurgery 59 4 (2006) 902-909 [discussion: 909-10]
65. Rapp M., Ozcan Z., Steiger H.J., et al. Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J Neurosurg 105 1 (2006) 41-50
66. Hickey W.F. Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol 11 2 (1999) 125-137
67. Elliott L.H., Brooks W.H., and Roszman T.L. Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas. J Neurosurg 67 2 (1987) 231-236
68. Baecher-Allan C., and Anderson D.E. Regulatory cells and human cancer. Semin Cancer Biol 16 2 (2006) 98-105
69. Brusko T.M., Putnam A.L., and Bluestone J.A. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 223 (2008) 371-390
70. Sakaguchi S., Yamaguchi T., Nomura T., et al. Regulatory T cells and immune tolerance. Cell 133 5 (2008) 775-787
71. Shimizu J., Yamazaki S., and Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163 10 (1999) 5211-5218
72. Belkaid Y., and Rouse B.T. Natural regulatory T cells in infectious disease. Nat Immunol 6 4 (2005) 353-360
73. Dwyer K.M., Deaglio S., Gao W., et al. CD39 and control of cellular immune responses. Purinergic Signal 3 1-2 (2007) 171-180
74. Fecci P.E., Mitchell D.A., Whitesides J.F., et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66 6 (2006) 3294-3302
75. El Andaloussi A., and Lesniak M.S. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 8 3 (2006) 234-243
76. Heimberger A.B., Abou-Ghazal M., Reina-Ortiz C., et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 14 16 (2008) 5166-5172
77. Ebert L.M., Tan B.S., Browning J., et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 68 8 (2008) 3001-3009
78. Berzofsky J.A., and Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 180 6 (2008) 3627-3635
79. Moodycliffe A.M., Nghiem D., Clydesdale G., et al. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 1 6 (2000) 521-525
80. Park J.M., Terabe M., van den Broeke L.T., et al. Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int J Cancer 114 1 (2005) 80-87
81. Terabe M., and Berzofsky J.A. The role of NKT cells in tumor immunity. Adv Cancer Res 101 (2008) 277-348
82. Terabe M., Matsui S., Park J.M., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198 11 (2003) 1741-1752